Zimmer Biomet saw a strong first quarter, and U.S. growth in particular was bolstered by the hip franchise, CEO Ivan Tornos said in an earnings call.
“Our U.S. hip franchise grew 5% in the quarter as we are seeing increasing traction of our hip triple-play of Z1, which now represents nearly 40% of our U.S. hip stems, OrthoGrid, our AI-based hip navigation platform, and HAMMR, our surgical impactor,” Mr. Tornos said, as transcribed by Morningstar.
Part of Zimmer Biomet’s hip strategy also includes its acquisitions. Notable deals in recent years include OrthoGrid Systems and Paragon 28.
“…Our recent acquisitions are all seeing positive momentum,” Mr. Tornos said. “Paragon 28 first quarter growth accelerated around 200 basis points from the fourth quarter of 2025 and is trending back towards double-digit growth performance. OrthoGrid delivered its strongest quarter to date with significant growth and accelerated adoption, solidifying OrthoGrid as a core driver of our digital ecosystem and anterior hip triple play.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
